← Eichor
Study identifier: NCT04516057 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Nabilone for Agitation Blinded Intervention Trial

Condition: Alzheimer Disease · Agitation  ·  Sponsor: Sunnybrook Health Sciences Centre

PhasePhase 3
Planned participants112
Who can joinAll sexes, 55 Years to no upper limit
Healthy volunteersNo

About this study

This study will look at whether nabilone is an effective treatment for agitation in Alzheimer's disease (AD) patients. Agitation is highly prevalent in patients with AD and is one of the most distressing and challenging-to-treat symptoms. Agitation is associated with faster progression to institutionalization, increased caregiver burden, poorer quality of life, and increased risk of death. In addition, current pharmacological options show only modest efficacy and elevated risks of adverse events. Therefore, identifying safer and more effective treatments for agitation in AD is a clinical and research priority. Nabilone is a synthetic cannabinoid that is Health Canada-approved to treat chemotherapy-induced nausea and vomiting. The PI's research group completed a 6-week double-blind placebo-controlled randomized cross-over pilot trial in 38 patients with moderate-to-severe AD, providing the first preliminary evidence regarding the safety and efficacy of nabilone in this population. They found that nabilone significantly improved agitation, overall neuropsychiatric symptoms, and caregiver distress. That study was limited by its sample size and questions remain regarding the efficacy of nabilone for nutrition and pain and predictors of response. However, the promising preliminary findings encourage a pivotal, practice-changing phase III trial to inform clinical practice. Participants in this study will be randomized to receive either nabilone or a placebo for 8 weeks. In addit…

This description comes directly from the study's public registry record.

Talk to the study team

NAB-IT Coordinating Centre  ·  416-480-6100  ·  NAB-IT@sunnybrook.ca

Always discuss trial participation with your own doctor first.

Locations (6)

University of CalgaryCalgary, Alberta, CanadaRecruiting
London Health Sciences CentreLondon, Ontario, CanadaRecruiting
Sunnybrook Health Sciences CentreToronto, Ontario, CanadaRecruiting
Centre for Addiction and Mental HealthToronto, Ontario, CanadaRecruiting
St. Michael's HospitalToronto, Ontario, CanadaRecruiting
Ontario Shores Centre for Mental Health SciencesWhitby, Ontario, CanadaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04516057